Silence Therapeutics plc (SLN) Financials

SLN Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 115.1 million 65.7 million
Dec. 31, 2025 131.4 million 69.1 million
Sept. 30, 2025 146.8 million 72.7 million
June 30, 2025 165.2 million 71.1 million

SLN Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -15.6 million 2.4 million
Dec. 31, 2025 -17.3 million 7.3 million
Sept. 30, 2025 -10.9 million 2.5 million
June 30, 2025 -21.8 million 2.1 million

SLN Net Income

No data available :(

SLN Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 70.1 million - 42999
Dec. 31, 2025 85.1 million - 71000
Sept. 30, 2025 102.2 million - 182000
June 30, 2025 114.2 million - -

SLN Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 47.2 million
Dec. 31, 2025 47.2 million
Sept. 30, 2025 15.7 million
June 30, 2025 15.7 million

SLN Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 8.3 million 7.0 million -
Dec. 31, 2025 55000 8.7 million 3.7 million -
Sept. 30, 2025 3000 20.5 million 5.8 million -
June 30, 2025 48000 24.2 million 7.0 million -

SLN Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 421292 116803
Dec. 31, 2025 34000 12000
Sept. 30, 2025 159000 64000
June 30, 2025 307544 85000

SLN Revenue by Segment

Graph available only for paid members. Upgrade to see it.

SLN

Price: $6.69

52 week price:
4.19
8.40

Earnings Per Share: -1.62 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 18800

Market Capitalization: 302.8 million

Links: